LOBE SCIENCES LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.02 CAD | +33.33% |
|
0.00% | -20.00% |
| Feb. 15 | Lobe Sciences Ltd. Reports Earnings Results for the Full Year Ended August 31, 2023 | CI |
| 2023 | Lobe Sciences Provides Update on L-130 Clinical Program | MT |
| Sales 2022 | - | Sales 2023 | 841K 615K | Capitalization | 3.88M 2.84M |
|---|---|---|---|---|---|
| Net income 2022 | -12M -8.78M | Net income 2023 | -4M -2.93M | EV / Sales 2022 | - |
| Net cash position 2022 | 933K 683K | Net Debt 2023 | 112K 81.92K | EV / Sales 2023 | 4.75 x |
| P/E ratio 2022 |
-0.29
x | P/E ratio 2023 |
-0.55
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 97.6% |
More Fundamentals
* Assessed data
More news
| 1 day | +33.33% | ||
| Current year | -20.00% |
1 week
0.02
0.02
1 month
0.020.02
Current year
0.020.03
1 year
0.010.04
3 years
0.010.87
5 years
0.011.80
10 years
0.011.80
| Managers | Title | Age | Since |
|---|---|---|---|
Philip Young
CEO | Chief Executive Officer | 66 | 21-01-14 |
Mathew Lee
DFI | Director of Finance/CFO | 40 | 23-09-17 |
Maghsoud Dariani
CTO | Chief Tech/Sci/R&D Officer | - | 20-07-20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Philip Young
CEO | Chief Executive Officer | 66 | 21-01-14 |
Baxter Phillips
COO | Chief Operating Officer | 48 | 22-10-02 |
Michael Petter
BRD | Director/Board Member | - | 21-01-07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 0.02 | +33.33% | 5,000 |
| 24-04-19 | 0.015 | -25.00% | 96,383 |
| 24-04-18 | 0.02 | 0.00% | 3,000 |
| 24-04-16 | 0.02 | +33.33% | 22,752 |
Delayed Quote Canadian Securities Exchange, April 23, 2024 at 03:59 pm EDT
More quotes
Lobe Sciences Ltd. is a Canada-based biopharmaceutical company focused on developing patient-friendly, practical psychedelic medicines. The Company, through collaborations with partners, is engaged in drug research and development using sub-hallucinatory doses of proprietary compounds to treat Orphan diseases. Its new chemical entities, L-130 and L-131, are being developed to address unmet medical needs such as Chronic Cluster Headaches and other Orphan diseases. In addition, the Company is commercializing Altemia, for the treatment of patients diagnosed with Sickle Cell Disease. Its subsidiaries include Eleusian Biosciences Corp., Lobe Sciences Australia Pty Ltd. and Altemia & Company, LLC.
Sector
Pharmaceuticals
Calendar
2024-04-28
- Q2 2024 Earnings Release (Projected)
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.00% | 2.4M | |
| +37.37% | 6.05B | |
| -15.69% | 4.45B | |
| -12.46% | 3.06B | |
| -0.12% | 3.04B | |
| +0.47% | 2.58B | |
| +36.06% | 1.79B | |
| +0.84% | 1.66B | |
| -10.60% | 1.63B | |
| -12.03% | 1.54B |
- Stock Market
- Equities
- LOBE Stock
